The landscape of drug discovery is undergoing a profound transformation. What began as a pandemic-era necessity—the digitization of pathology slides to facilitate remote work—has evolved into a sophisticated technological frontier. Today, digital pathology is moving beyond simple remote viewing, becoming a powerhouse for extracting deep, latent biological insights from existing tissue archives. By leveraging artificial intelligence and advanced image analysis, researchers are finding that they can "mine" historical data to answer modern questions, ultimately reducing the reliance on new animal studies and aligning with a global regulatory shift toward New Approach Methodologies (NAMs).
The Main Facts: From Static Reports to Dynamic Data
Traditionally, the workflow of a pathologist was linear and, in many ways, terminal. A tissue sample was prepared, mounted on a glass slide, examined, and summarized in a report. Once that report was signed, the glass slide was relegated to long-term storage, its data effectively locked away.
"Before, the pathology endpoint was just a report," explains Dr. Aleksandra Zuraw, a veterinary pathologist at Charles River Laboratories. "Now, you have the digitized slide, which is essentially a treasure trove of pixels."
This paradigm shift is defined by the transition from static observation to computational analysis. By coupling high-resolution digital images with molecular data and historical pathology reports, researchers can train machine learning models to identify subtle patterns—molecular signatures of disease or toxicity—that were previously invisible to the human eye. The slide is no longer a "one-way street" ending in a filing cabinet; it is now a reusable asset capable of providing data for secondary research questions without requiring additional animal subjects.
Chronology: A Trajectory Toward Modernization
The modernization of preclinical research is not an overnight phenomenon but a culmination of years of technological and regulatory convergence.
- 2020–2021: The COVID-19 pandemic serves as the catalyst. Faced with lockdowns, laboratories worldwide accelerate the adoption of digital pathology scanners to allow pathologists to sign out cases from home.
- 2022: The United States enacts the FDA Modernization Act 2.0, a landmark piece of legislation that officially permits the use of non-animal methods to support human clinical trial applications, signaling a departure from the "animal-first" regulatory mandate.
- April 2024: Charles River Laboratories launches its "Alternative Methods Advancement Project," a strategic initiative aimed at reducing, refining, and replacing animal testing through technological innovation.
- April 2025: The FDA releases its comprehensive roadmap for reducing animal testing in preclinical safety studies. The document outlines a multi-year strategy, beginning with monoclonal antibodies and gradually expanding to chemical entities.
- September 2026: The FDA provides further regulatory updates, solidifying the role of NAMs as a standard component of safety assessment.
Supporting Data: Innovations in Virtualization
The drive to reduce animal usage is supported by two primary technological pillars: virtual control groups and the secondary use of formalin-fixed, paraffin-embedded (FFPE) tissue blocks.
The Rise of Virtual Control Groups
In conventional toxicology studies, a significant percentage of animals are assigned to "control groups"—subjects that undergo the same procedures as the treatment group but receive no drug. This is done to establish a baseline. However, if a lab has an extensive database of high-quality, historical control data from previous, identical studies, those animals can be replaced by "virtual controls." By utilizing matched historical data, laboratories can mathematically reduce the number of animals required for new studies without sacrificing statistical power.
Unlocking the FFPE Archive
The physical storage of tissue—the FFPE blocks—holds immense untapped potential. While fresh-frozen samples are ideal for some molecular analyses, researchers often find themselves asking new questions about a drug’s mechanism of action long after a study has concluded.
"So now you have the option to use FFPE material that was already part of a lot of studies for additional information," says Dr. Zuraw. "You don’t lose the context of the study."
By performing omics analysis (gene expression and protein profiling) on these archived samples, researchers can derive deep insights into how a drug affected cellular signaling pathways. Furthermore, the OECD’s 2025 guidance on sample collection for omics has provided the necessary framework to ensure that such analyses are scientifically rigorous, helping to standardize the quality of data derived from preserved tissues.
Official Responses and Regulatory Shifts
The regulatory environment has shifted from viewing animal testing as the "gold standard" to treating it as a component of a larger, integrated safety assessment. The FDA’s roadmap is explicit in its goal: within three to five years, the agency aims to position NAMs as the default, with animal studies reserved for cases where alternative methods are not yet sufficient.
This regulatory backing is crucial because, as Dr. Zuraw notes, the adoption of these technologies requires "early adopters." Laboratories need to generate precedent—demonstrating through pilot studies that virtual staining, AI-driven histopathology, and virtual controls provide outcomes as reliable as, or better than, traditional methods.
The Power of Virtual Staining
Perhaps the most "cutting-edge" development in this space is virtual staining. This technology allows researchers to scan unstained tissue sections and use software to generate the appearance of a stain (such as H&E). This potentially eliminates the need for chemical reagents and glass slide preparation entirely. As more labs transition to fully digital workflows, the cost-benefit analysis for adopting these systems becomes increasingly favorable, creating what Dr. Zuraw describes as a "snowball effect."
Implications for the Future of Drug Discovery
The implications of this shift are far-reaching, affecting ethical, financial, and scientific dimensions of pharmaceutical development.
1. Ethical Stewardship
The most immediate benefit is the reduction of animal usage, directly addressing the ethical imperative to refine and replace animal models whenever possible. By extracting more data from fewer animals, the industry demonstrates a commitment to the 3Rs (Replacement, Reduction, and Refinement).
2. Economic Efficiency
Traditional drug development is notoriously expensive and time-consuming. By mining archived data, companies can bypass the need for "repeat" experiments. If a question arises regarding organ toxicity, and the data already exists within a digitized slide or an FFPE block, the financial savings are immense. Faster, more data-rich decisions lead to shorter development timelines, potentially bringing life-saving drugs to market more quickly.
3. Scientific Precision
Digital pathology is inherently more quantitative than human observation. While a pathologist is limited by the subjective nature of visual inspection, an AI algorithm can measure nuclear size, cell density, and spatial relationships across thousands of slides with perfect consistency. This leads to higher reproducibility and a more granular understanding of how compounds interact with biological systems at the molecular level.
4. Overcoming the Adoption Hurdle
Despite the clear benefits, the industry faces a challenge in training and culture. Moving a department of nearly a hundred pathologists to a digital sign-out system is a monumental task. Yet, as leaders in the field—such as those discussed in Dr. Zuraw’s professional outreach and podcasts—continue to share their implementation strategies, the barrier to entry lowers.
Conclusion: A New Era of "Data-First" Pathology
We are witnessing the end of the "static slide" era. As digital pathology matures, the focus of the pharmaceutical industry is shifting toward a "data-first" mindset. The tissue blocks sitting in storage today are no longer relics of past experiments; they are the training data for the next generation of predictive models.
By embracing the regulatory guidance of the FDA and the OECD, and by fostering a community of early adopters who troubleshoot and refine these digital workflows, the scientific community is building a more efficient, ethical, and precise engine for drug discovery. The goal is clear: to move toward a future where animal studies are the exception, and where the information contained within our archives is harnessed to its full, life-saving potential.
About the Author
